Downloads: 1
Original Article | Psychiatry | Volume 15 Issue 2, February 2026 | Pages: 1561 - 1567 | Canada
ADHD Management in Practice: Why the Choice of Methylphenidate Formulation Matters for Restorative Functionality
Abstract: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Stimulant medications remain a cornerstone of ADHD multimodal management. Methylphenidate extended release (ER) is available in osmotic and non-osmotic formulations. The osmotic delivery system used in the Osmotic-Controlled Release Oral Delivery System (OROS) methylphenidate ER (Concerta ®) functions like a precision biomedical device, using osmotic pressure to provide a release profile that ensures symptom control throughout the day. Clinical guidelines and real-world data suggest that osmotic and non-osmotic delivery formulations are not interchangeable and achieving restorative functionality can be influenced by the choice of delivery system. No historically available generic non-OROS methylphenidate ER to date has been demonstrated to provide consistent results across the past 15 years. Thus, the osmotic delivery system is more than the medication; it is a technology that safely and predictably delivers medication to restore functionality for patients with ADHD. Only now, with Taro-Methylphenidate ER, has an osmotic delivery system technology been available in a subsequent entry methylphenidate ER product.
Keywords: methylphenidate, ADHD, osmotic delivery system, extended-release, restorative functionality
How to Cite?: Joel Lamoure, Dr. Angelo Fallu, Dr. Kenny Handelman, Dr. Martin Katzman, "ADHD Management in Practice: Why the Choice of Methylphenidate Formulation Matters for Restorative Functionality", Volume 15 Issue 2, February 2026, International Journal of Science and Research (IJSR), Pages: 1561-1567, https://www.ijsr.net/getabstract.php?paperid=SR26223193548, DOI: https://dx.dx.doi.org/10.21275/SR26223193548